All News

Health care is inherently human, so digital health care technology aimed at advancing human health needs empathy to be successful.

The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.

The COVID-19 vaccine may generally increase oxygenation ability, which could lead to lower mortality in patients who are treated using invasive mechanical ventilation.

Pharmaceutical companies are looking into AI as the new method to not only reduce research and development costs, but also prevent costly errors.

As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.

Previous studies have shown that PAD also impacts health status and functioning.

Further, the survey showed that fewer than half of women would flag redness of the breast, thickening of the skin, or 1 breast feeling warmer and heavier than the other as possible symptoms.

Researchers suggest that tapering a patient’s opioid medications and allowing them to maintain a health care plan can decrease the risk of developing opioid use disorder among other negative outcomes.

Rami Elghandour, chairman and CEO of Arcellx, discussed the company’s investigative CAR-modified T-cell therapy.

Because we need to be prepared and respond to future crises, making these changes permanent is a top priority for the profession of pharmacy.

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

Latest Information is key to helping patients stay healthy amid continuously changing landscape.

As a part of the Women in Pharmacy series, Vibhuti Arya, PharmD, MPH, FAPhA, global lead, Gender Equity and Diversity Workforce Development at FIP, discusses moments that shaped her vision for her career in pharmacy.

Research indicates quadruplet regimens may be a viable option for this disease.

A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.

Presentation at the AMCP Nexus conference focuses on midterm election outlook and a plug for the Pre-approval Information Exchange Act.

This World Standards Week, Carrie Harney, JD, vice president, US Government and Regulatory Affairs at US Pharmacopeia (USP), explains how pharmacists contribute to USP’s standards setting process.

The study will evaluate the safety, tolerability, and efficacy of the in combination in patients both with and without prior exposure to a KRASG12C inhibitor.

As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.

The process of supporting a cause for our profession can be highly rewarding. As pharmacists, we must take charge to enact change.

Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.

The drug shows improvement in exercise capacity and key secondary outcomes compared with the placebo when added to background therapy for those with pulmonary arterial hypertension.

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

Keynote speaker at the AMCP Nexus conference discusses recent FDA approvals and those scheduled over the next year.

In the trial, randomized patients with UC who received corticosteroids at maintenance baseline were able to eliminate the use of corticosteroids by week 200.

Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.